Search Immortality Topics:

Page 4«..3456..1020..»


Category Archives: Global News Feed

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors

See the original post:
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Posted in Global News Feed | Comments Off on Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed to extend the interest-only period of its existing loan by eighteen months.

See the original post here:
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Posted in Global News Feed | Comments Off on Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.

Read more:
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Posted in Global News Feed | Comments Off on Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Link:
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

Posted in Global News Feed | Comments Off on Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has streamlined its executive leadership to further focus on advancing the Company’s clinical programs while optimizing resource allocation. As part of this effort, Senior Vice President, Chief Commercial Officer, Robert Francomano and Executive Vice President, General Counsel and Corporate Secretary, Barbara Wood, will be departing the Company.

Go here to read the rest:
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Posted in Global News Feed | Comments Off on SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024

See more here:
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Posted in Global News Feed | Comments Off on Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights